Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.

ABSTRACT:

Objective

This study tested the hypothesis that phosphodiesterase 5 inhibition alone or in combination with ACE inhibition improves glucose homeostasis and fibrinolysis in individuals with metabolic syndrome.

Research design and methods

Insulin sensitivity, beta-cell function, and fibrinolytic parameters were measured in 18 adults with metabolic syndrome on 4 separate days after a randomized, crossover, double-blind, 3-week treatment with placebo, ramipril (10 mg/day), tadalafil (10 mg o.d.), and ramipril plus tadalafil.

Results

Ramipril decreased systolic and diastolic blood pressure, ACE activity, and angiotensin II and increased plasma renin activity. Ramipril did not affect insulin sensitivity or beta-cell function. In contrast, tadalafil improved beta-cell functi

SUBMITTER: Hill KD 

PROVIDER: S-EPMC2671107 | biostudies-literature | 2009 May

REPOSITORIES: biostudies-literature